BYSI BeyondSpring

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.

The conference call may be accessed by dialing 877-451-6152 (U.S.) or 201-389-0879 (International) and referencing conference ID: 13720525. A live webcast will be available on BeyondSpring’s website at under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 90 days.

About BeyondSpring

Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class NDA-stage lead asset plinabulin, a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), is a “pipeline in a drug.” It is filed for approval with Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study (Dublin-3) to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:

Ashley R. Robinson

LifeSci Advisors, LLC



Media Contact:

Darren Opland, Ph.D.

LifeSci Communications





EN
11/06/2021

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentat...

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the , taking place on April 17 through 22, 2026 in San Diego, California. Presentation Details: Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or...

March 30, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Files 2025 Annual Report on Form 10-K

BeyondSpring Files 2025 Annual Report on Form 10-K FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2026. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at ...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports 2025 Year-End Financial Results

BeyondSpring Reports 2025 Year-End Financial Results Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Co...

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in , held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical devel...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxe...

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immun...

December 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch